ArticleNanomaterials (Basel, Switzerland)2022
Cancer Diagnosis Using Terahertz-Graphene-Metasurface-Based Biosensor with Dual-Resonance Response.
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Article
- Synergistic terahertz platforms for precision oncology.Theranostics · 2026Review
- A simulation-based plasmonic terahertz nanosensor with graphene-enhanced sensitivity for diabetes monitoring.Scientific reports · 2025Article
- Metasurface-assisted bioelectronics: bridging photonic innovation with biomedical implants.Light, science & applications · 2025Article
- Metasurface-enhanced biomedical spectroscopy.Nanophotonics (Berlin, Germany) · 2025Review
- Design and validation of ultra-compact metamaterial-based biosensor for non-invasive cervical cancer diagnosis in terahertz regime.PloS one · 2025Article
- Triple-band highly sensitive terahertz metamaterial absorber for biomedical sensing applications.PloS one · 2025Article
- Ultra-compact quintuple-band terahertz metamaterial biosensor for enhanced blood cancer diagnostics.PloS one · 2025Article
- Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas.Molecules (Basel, Switzerland) · 2023Review
- Metasurface-Assisted Terahertz Sensing.Sensors (Basel, Switzerland) · 2023Review
- Angular-Dependent THz Modulator with Hybrid Metal-Graphene Metastructures.Nanomaterials (Basel, Switzerland) · 2023Article
- A Voltage-Tuned Terahertz Absorber Based on MoSNanomaterials (Basel, Switzerland) · 2023Article
- Gaussian Curvature Effects on Graphene Quantum Dots.Nanomaterials (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Owing to the outstanding physical properties of graphene, its biosensing applications implemented by the terahertz metasurface are widely concerned and studied. Here, we present a novel design of the graphene metasurface, which consists of an individual graphene ring and an H-shaped graphene structure. The graphene metasurface exhibits a dual-resonance response, whose resonance frequency strongly varies with the geometrical parameters of the proposed metasurface, the carrier density of graphene, and the analyte composition. The transparency window, including width and position, can be artificially controlled by adjusting the geometrical parameters or the Fermi energy. Furthermore, the sensing parameters of the graphene metasurface for cancerous and normal cells are investigated, focusing on two factors, namely cell quantity and position on the metasurface. The simulated results clearly show that the theoretical sensitivity, figure of merit, and quantity of the graphene metasurface for breast cells reach 1.21 THz/RIU, 2.75 RIU-1, and 2.43, respectively. Our findings may open up new avenues for promising applications in the diagnosis of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.